Ticker archive · $BHVN

$BHVN Filing Signals & Market Reactions

Delayed, SEO-crawlable recaps of AI-scored catalysts for $BHVN — including observed post-filing price moves. Live streaming stays exclusive to VIP.

? All delayed signals

$BHVN

$BHVN – Biohaven Reports FDA Acceptance of Vyglxia NDA, $400M License Agreement, Q3 Net Loss of $0.86/Share

Biohaven Ltd.

2026-10-29 00:00:00 UTC · SEC_8K · All $BHVN

?? Positive AI Sentiment (+6.5 / 10)

FDA accepted NDA resubmission for troriluzole (Vyglxia) in SCA with PDUFA goal date in 1Q27.
Exclusive global license deal signed with SK Biopharma provides $400M near-term cash consideration.
Q3 net loss narrowed to $129.3M ($0.86/share) vs. $173.4M ($1.64/share) YoY; cash reserves stood at $95.8M.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?